Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVLO Stock Price Chart Interactive Chart >
EVLO Price/Volume Stats
| Current price | $5.24 | 52-week high | $19.93 |
| Prev. close | $5.21 | 52-week low | $4.65 |
| Day low | $5.12 | Volume | 93,162 |
| Day high | $5.33 | Avg. volume | 240,222 |
| 50-day MA | $7.31 | Dividend yield | N/A |
| 200-day MA | $9.89 | Market Cap | 280.13M |
Evelo Biosciences, Inc. (EVLO) Company Bio
Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Latest EVLO News From Around the Web
Below are the latest news stories about Evelo Biosciences Inc that investors may wish to consider to help them evaluate EVLO as an investment opportunity.
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory DiseasesCAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January |
Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming CatalystsCAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced its strategic priorities and upcoming catalysts for 2022. “In 2021 we announced positive Phase 2 clinical data for our first SINTAX-based medicine EDP1815 in psoriasis, demonstrating that EDP1815 is a potential medicine that can be delivered orally t |
Evelo Biosciences picked for addition to Nasdaq Biotechnology IndexNo summary available. |
Evelo Biosciences Added to Nasdaq Biotechnology IndexCAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the Company has been added to the NASDAQ Biotechnology Index ® (Nasdaq: NBI), effective prior to market open on December 20, 2021. |
Goldman Sachs Group Inc. Purchases 12,716 Shares of Evelo Biosciences, Inc. (NASDAQ:EVLO)Goldman Sachs Group Inc. boosted its position in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) by 90.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,779 shares of the companys stock after purchasing an additional 12,716 shares during the quarter. Goldman Sachs Group Inc.s holdings [] |
EVLO Price Returns
| 1-mo | -23.50% |
| 3-mo | -36.64% |
| 6-mo | -43.11% |
| 1-year | -67.95% |
| 3-year | -39.21% |
| 5-year | N/A |
| YTD | -13.67% |
| 2021 | -49.79% |
| 2020 | 197.78% |
| 2019 | -68.79% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...